3. Segment Information

12 Months Ended

Jun. 30, 2022

Segment Information

3. Segment Information

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the manufacture, design, and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

Year Ended June 30, 2022	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate			Consolidated
Revenues	$	9,981,100	$	1,419,400		$	-		$	11,400,500
Foreign Sales		3,702,400		1,101,400			-			4,803,800
Income (Loss) From Operations		1,475,800		(7,089,400	)		(1,650,400	)		(7,264,000	)
Assets		9,538,600		10,402,800			9,090,200			29,031,600
Long-Lived Asset Expenditures		92,500		732,100			-			824,600
Depreciation and Amortization		96,300		591,900			-			688,200

Year Ended June 30, 2021	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate			Consolidated
Revenues	$	9,043,600	$	731,600		$	-		$	9,775,200
Foreign Sales		3,483,700		684,600			-			4,168,300
Income (Loss) From Operations		1,461,300		(4,828,600	)		(1,341,400	)		(4,708,700	)
Assets		14,783,000		8,735,100			5,488,300			29,006,400
Long-Lived Asset Expenditures		60,500		196,900			-			257,400
Depreciation and Amortization		103,100		148,400			-			251,500